Valuation: Gilead Sciences, Inc.

Capitalization 165B 142B 129B 123B 227B 15,818B 229B 1,545B 600B 7,502B 620B 607B 26,157B P/E ratio 2026 *
-47.7x
P/E ratio 2027 * 17x
Enterprise value 175B 150B 137B 130B 240B 16,734B 242B 1,634B 635B 7,937B 656B 642B 27,672B EV / Sales 2026 *
5.74x
EV / Sales 2027 * 5.11x
Free-Float
99.87%
Yield 2026 *
2.46%
Yield 2027 * 2.51%
1 day+1.89%
1 week-3.11%
Current month+0.93%
1 month-5.01%
3 months-14.79%
6 months+5.48%
Current year+7.59%
1 week 129
Extreme 129
137.5
1 month 127.64
Extreme 127.64
140.96
Current year 116.88
Extreme 116.88
157.29
1 year 97.86
Extreme 97.86
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5d. change 1-year change 3-years change Capi.($)
-0.74%-3.11%+30.20%+68.94% 165B
-0.89%+1.99%+34.94%+131.73% 906B
+0.16%+2.75%+55.48%+43.55% 555B
+1.09%+2.80%+12.11%+43.23% 368B
-0.94%-2.05%+21.74%+10.73% 326B
-0.19%+1.28%+34.97%+14.40% 289B
+0.78%+1.00%+29.63%+26.23% 285B
-0.04%-0.13%+48.00%-3.18% 280B
+0.91%+2.12%-31.78%-49.10% 208B
-0.07%+1.55%+24.32%+44.34% 182B
Average +0.26%+0.74%+25.96%+33.09% 356.36B
Weighted average by Cap. +0.10%+1.08%+30.52%+51.32%

Financials

2026 *2027 *
Net sales 30.43B 26.07B 23.85B 22.71B 41.73B 2,914B 42.15B 285B 111B 1,382B 114B 112B 4,818B 32.31B 27.69B 25.32B 24.11B 44.32B 3,094B 44.75B 302B 117B 1,468B 121B 119B 5,116B
Net income -3.5B -3B -2.74B -2.61B -4.8B -335B -4.85B -32.73B -12.72B -159B -13.14B -12.86B -554B 9.68B 8.3B 7.59B 7.22B 13.28B 927B 13.41B 90.54B 35.17B 440B 36.33B 35.56B 1,533B
Net Debt 9.57B 8.2B 7.5B 7.14B 13.12B 916B 13.25B 89.48B 34.76B 435B 35.9B 35.14B 1,515B -96.43M -82.63M -75.57M -71.96M -132M -9.23B -134M -902M -350M -4.38B -362M -354M -15.27B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
14/05/26 132.06 $ -0.74% 4,324,702
13/05/26 133.05 $ -1.40% 6,666,706
12/05/26 134.94 $ +1.06% 6,034,938
11/05/26 133.52 $ +1.67% 5,384,970
08/05/26 131.33 $ -2.04% 10,250,367
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
132.06USD
Average target price
157.96USD
Spread / Average Target
+19.62%

Quarterly revenue - Rate of surprise